Literature DB >> 153146

Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis.

G E Marlin, D E Bush, N Berend.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 153146      PMCID: PMC1429707          DOI: 10.1111/j.1365-2125.1978.tb00885.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  VARIATION OF DRUG ACTION ON AIRWAY OBSTRUCTION IN MAN.

Authors:  R E ALTOUNYAN
Journal:  Thorax       Date:  1964-09       Impact factor: 9.139

2.  Of pediatrics and geriatrics.

Authors:  B R Meyerowitz
Journal:  West J Med       Date:  1978-06

3.  Aerosol therapy with Sch 1000. Short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects.

Authors:  R E Ruffin; R K Wolff; M B Dolovich; C M Rossman; J D Fitzgerald; M T Newhouse
Journal:  Chest       Date:  1978-04       Impact factor: 9.410

4.  A comparison of responses to bronchodilator drugs in chronic bronchitis and chronic asthma.

Authors:  G K Crompton
Journal:  Thorax       Date:  1968-01       Impact factor: 9.139

5.  Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma.

Authors:  G R Petrie; K N Palmer
Journal:  Br Med J       Date:  1975-02-22

6.  Bronchial responsiveness to inhaled histamine and isoprenaline in patients with airway obstruction.

Authors:  M K Benson
Journal:  Thorax       Date:  1978-04       Impact factor: 9.139

7.  Comparative bronchodilator responses to atropine and terbutaline in asthma and chronic bronchitis.

Authors:  T W Chick; J W Jenne
Journal:  Chest       Date:  1977-12       Impact factor: 9.410

8.  Effect of aerosol ipratropium bromide (SCH 1000) on sputum viscosity and volume in chronic bronchitis.

Authors:  C S May; K N Palmer
Journal:  Br J Clin Pharmacol       Date:  1977-08       Impact factor: 4.335

  8 in total
  8 in total

1.  Dose-titration comparison of inhaled salbutamol and oral theophylline in asthma.

Authors:  G E Marlin; M R Harris; J A Klumpp; J Rutland
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

Review 2.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 3.  Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease.

Authors:  Mario Cazzola; Maria G Matera; Claudio F Donner
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation.

Authors:  I G Brown; C S Chan; C A Kelly; A G Dent; P V Zimmerman
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

Review 5.  Parasite-bacteria interrelationship.

Authors:  Dalia S Ashour; Ahmad A Othman
Journal:  Parasitol Res       Date:  2020-08-04       Impact factor: 2.289

Review 6.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 7.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

8.  Bronchodilator responses to nebulised ipratropium and salbutamol singly and in combination in chronic bronchitis.

Authors:  C S Chan; I G Brown; C A Kelly; A G Dent; P V Zimmerman
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.